Dermata Therapeutics, Inc. (DRMA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Dermatologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
CRITICAL DILUTION RISKDilution score: 87/100 (CRITICAL), 6.0 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 3.79% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories
- Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
- Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
- Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
- Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
- Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
- Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
- Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Dermata Therapeutics, Inc..
Full DRMA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.